A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas

Abstract

Supriya Mallick

Introduction Malignant gliomas are the most common primary malignant brain tumors and are typically treated with maximal safe surgical resection followed by chemoradiation. One of the unintended effects of radiation is depletion of circulating lymphocyte pool, which has been correlated with inferior overall survival outcomes.

Methods A comprehensive and systematic searches of the PubMed, Cochrane Central, and Embase databases were done to assess the studies that have reported radiation-related lymphopenia in high-grade gliomas. Hazard ratios (HRs), odds ratios (OR), and mean differences were represented with Forest plots comparing patients with severe lymphopenia and no severe lymphopenia. Review Manager Version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for the analysis.

Results Nineteen studies were included in the final systematic review and 12 studies were included in the meta-analysis. The odds of developing severe lymphopenia were 0.39 (95% CI:0.19, 0.81, I ² = 94%, p = 0.01). Patients with severe lymphopenia were at increased risk of death with a pooled HR = 2.19 (95% CI: 1.70, 2.83, I ² = 0%, p <0.00001) compared to patients with no severe lymphopenia. The mean difference in survival between patients with severe lymphopenia and no severe lymphopenia was −6.72 months (95% CI: −8.95, −4.49, I ² = 99%, p <0.00001), with a better mean survival in the no severe lymphopenia group.

Conclusion Radiation-induced severe lymphopenia was associated with poor overall survival and increased risk of death. Photon therapy, larger planning target volume, higher brain dose, higher hypothalamus dose, and female gender were associated with increased risk of severe lymphopenia.

Keywords

radiation - lymphopenia - high-grade gliomas - systematic review

Publikationsverlauf

Artikel online veröffentlicht:
23. August 2022

• References

• 1 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol 2012; 14 (Suppl. 05) v1-v49
• 2 Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310 (17) 1842-1850
• 3 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
• 4 Stupp R, Hegi ME, Mason WP. et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10 (05) 459-466
• 5 Dong X, Noorbakhsh A, Hirshman BR. et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neurooncol Pract 2016; 3 (01) 29-38
• 6 Lohr J, Ratliff T, Huppertz A. et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 2011; 17 (13) 4296-4308
• 7 Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117 (05) 1137-1146
• 8 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480 (7378): 480-489
• 9 Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 2013; 31 (02) 140-144
• 10 Trowell OA. The sensitivity of lymphocytes to ionising radiation. J Pathol Bacteriol 1952; 64 (04) 687-704
• 11 Mohan R, Liu AY, Brown PD. et al. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro-oncol 2021; 23 (02) 284-294
• 12 Huang J, DeWees TA, Badiyan SN. et al. Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys 2015; 92 (05) 1000-1007
• 13 Ishikawa E, Yamamoto T, Sakamoto N. et al. Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. Neurol Med Chir (Tokyo) 2010; 50 (08) 638-644
• 14 Hui CY, Rudra S, Ma S, Campian JL, Huang J. Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients. J Neurooncol 2019; 143 (01) 129-136
• 15 Rudra S, Hui C, Rao YJ. et al. Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma. Int J Radiat Oncol Biol Phys 2018; 101 (01) 217-225
• 16 Byun HK, Kim N, Yoon HI. et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiat Oncol 2019; 14 (01) 51
• 17 Ye LL, Fan XW, Hu CS. et al. Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy. Cancer Med 2019; 8 (06) 2759-2768
• 18 Davuluri R, Jiang W, Fang P. et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys 2017; 99 (01) 128-135
• 19 Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 2013; 31 (03) 183-188
• 20 Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005; 14 (05) 1269-1273
• 21 Wild AT, Ye X, Ellsworth SG. et al. The association between chemoradiation related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2015; 38 (03) 259-265
• 22 Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 2012; 30 (08) 571-576
• 23 Campian JL, Sarai G, Ye X, Marur S, Grossman SA. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 2014; 36 (12) 1747-1753
• 24 Cho O, Chun M, Chang SJ, Oh YT, Noh OK. Prognostic value of severe lymphopenia during pelvic concurrent chemoradiotherapy in cervical cancer. Anticancer Res 2016; 36 (07) 3541-3547
• 25 Wu ES, Oduyebo T, Cobb LP. et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol 2016; 140 (01) 76-82
• 26 Harisiadis L, Kopelson G, Chang CH. Lymphopenia caused by cranial irradiation in children receiving craniospinal radiotherapy. Cancer 1977; 40 (03) 1102-1108
• 27 Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29 (01) 58-69
• 28 Bowman RL, Klemm F, Akkari L. et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep 2016; 17 (09) 2445-2459
• 29 Fecci PE, Mitchell DA, Whitesides JF. et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66 (06) 3294-3302
• 30 El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncol 2006; 8 (03) 234-243
• 31 Nitta T, Hishii M, Sato K, Okumura K. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 1994; 649 (1-2): 122-128
• 32 Jacobs JF, Idema AJ, Bol KF. et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-oncol 2009; 11 (04) 394-402
• 33 Heimberger AB, Abou-Ghazal M, Reina-Ortiz C. et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14 (16) 5166-5172
• 34 Kmiecik J, Poli A, Brons NHC. et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 2013; 264 (1-2): 71-83
• 35 Sayour EJ, McLendon P, McLendon R. et al. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 2015; 64 (04) 419-427
• 36 Grauer OM, Nierkens S, Bennink E. et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121 (01) 95-105
• 37 Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res 2008; 28 (2B): 1143-1150
• 38 Nduom EK, Wei J, Yaghi NK. et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-oncol 2016; 18 (02) 195-205
• 39 Hao C, Chen G, Zhao H. et al. PD-L1 expression in glioblastoma, the clinical and prognostic significance: a systematic literature review and meta-analysis. Front Oncol 2020; 10: 1015
• 40 Berghoff AS, Kiesel B, Widhalm G. et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-oncol 2015; 17 (08) 1064-1075
• 41 Wang Z, Zhang C, Liu X. et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology 2016; 5 (11) e1196310
• 42 Cao J-X, Zhang X-Y, Liu J-L. et al. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One 2014; 9 (09) e107173
• 43 Chongsathidkiet P, Jackson C, Koyama S. et al. S1P1 loss mediates T-cell sequestration in bone marrow amidst glioblastoma. Nat Med 2018; 24 (09) 1459-1468
• 44 Grossman SA, Ye X, Lesser G. et al; NABTT CNS Consortium. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17 (16) 5473-5480
• 45 Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol [Internet] 2016; 2016 Apr [cited 2022 Jul 3] 127 (02) 32935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783226/
• 46 Campian JL, Ye X, Gladstone DE, Ambady P, Nirschl TR, Borrello I. et al. Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. J Neurooncol [Internet] 2015 Sep [cited 2022 Jul 3];124(2):30716. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696006/
• 47 Lee C, Ahn S, Park JS, Song JH, Hong YK, Jeun SS. Effect of Cumulative Dexamethasone Dose during Concomitant Chemoradiation on Lymphopenia in Patients with Newly Diagnosed Glioblastoma. Brain Tumor Res Treat [Internet] 2020; Oct [cited 2021 Mar 20] 8 (02) 716 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595853/